Products
Platform
Research
Market
Learn
Compare Nippon India Pharma Fund vs DSP Healthcare Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 3.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.8 | 1.91 |
NAV | ₹530.79 | ₹40.32 |
Fund Started | 10 May 2004 | 12 Nov 2018 |
Fund Size | ₹8569.15 Cr | ₹3056.90 Cr |
Exit Load | Exit load of 1% if redeemed within 1 month. | Exit load of 0.50% if redeemed within 1 month. |
Risk
Very High
Very High
Rating
3.0
4.0
Min SIP Amount
₹100
₹100
Expense Ratio
1.8
1.91
NAV
₹530.79
₹40.32
Fund Started
10 May 2004
12 Nov 2018
Fund Size
₹8569.15 Cr
₹3056.90 Cr
Exit Load
Exit load of 1% if redeemed within 1 month.
Exit load of 0.50% if redeemed within 1 month.
Returns
1 Year | 8.47% | 7.88% |
3 Year | 24.46% | 24.97% |
5 Year | 20.23% | 21.24% |
1 Year
8.47%
7.88%
3 Year
24.46%
24.97%
5 Year
20.23%
21.24%
Holding Analysis
Equity | 99.43% | 98.31% |
Cash | 0.57% | 1.69% |
Equity
99.43%
98.31%
Cash
0.57%
1.69%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 12.23% |
Divi's Laboratories Ltd. | 8.50% |
Lupin Ltd. | 6.07% |
Cipla Ltd. | 5.62% |
Apollo Hospitals Enterprise Ltd. | 5.48% |
Dr. Reddy's Laboratories Ltd. | 5.18% |
Medplus Health Services Ltd. | 3.83% |
Glaxosmithkline Pharmaceuticals Ltd. | 3.63% |
Narayana Hrudayalaya Ltd. | 3.55% |
Vijaya Diagnostic Centre Ltd. | 3.32% |
Name | Assets |
|---|---|
Cipla Ltd. | 8.82% |
Sun Pharmaceutical Industries Ltd. | 8.42% |
Cohance Lifesciences Ltd. | 7.88% |
Ipca Laboratories Ltd. | 7.71% |
Gland Pharma Ltd. | 5.52% |
Laurus Labs Ltd. | 5.26% |
Alembic Pharmaceuticals Ltd. | 4.85% |
Apollo Hospitals Enterprise Ltd. | 4.61% |
Globus Medical Inc | 4.44% |
Sai Life Sciences Ltd. | 4.31% |
Fund Manager
Name | Akshay Sharma | Jay Kothari |
Start Date | 01 Dec 2022 | 16 Mar 2018 |
Name
Akshay Sharma
Jay Kothari
Start Date
01 Dec 2022
16 Mar 2018
About Fund
Description | The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies. | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. |
Launch Date | 10 May 2004 | 12 Nov 2018 |
Description
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
Launch Date
10 May 2004
12 Nov 2018
